期刊
RADIATION ONCOLOGY
卷 13, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13014-018-1178-8
关键词
Stereotactic radiosurgery; Brain metastases; Metastases surgery; Immune profiling; Molecular profiling
资金
- IU Health Values Fund (Indiana University Health) - Indiana CTSI (Clinical and Translational Science Institute), Indianapolis IN, USA [VFR-456-Dey]
BackgroundStereotactic radiosurgery (SRS) has emerged as a common adjuvant modality used with surgery for resectable brain metastases (BMs). However, the optimal sequence of the multi-modality therapy has not been established. The goal of the study is to evaluate 6-month local control utilizing pre-operative SRS followed by surgical resection for patients with 1-4 brain metastases.MethodsThis prospective, single arm, phase II trial will recruit patients with up to 4 brain metastases and at least one resectable lesion. All lesions will be treated with SRS and symptomatic lesions will be resected within 1-4days after SRS. Patients will be monitored for 6-month local control, in-brain progression free survival, distant in-brain failure, rate of leptomeningeal spread, radiation necrosis and overall survival. Additionally, we will also perform correlative radiobiological molecular studies to assess the effect of radiation dosing on the tumor tissue and clinical outcomes. We expect that pre-operative SRS to the gross tumor prior to surgical resection will improve local control and decrease leptomeningeal failure.DiscussionOur study is the second prospective trial to investigate the efficacy of pre-operative SRS in the treatment of multiple BMs. In addition, the correlative molecular studies will be the first to investigate early response of BMs at a cellular and genetic level in response to radiation doses and potentially provide molecular prognostic markers for local control and overall survival.Trial registrationClinicaltrials.gov identifier: NCT03398694 (registration date: January 12, 2018).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据